Evidence map›Paper›PMID 24332042›Full record

ArticleCancer cell2013

SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer.

Lianjie Li, Chuan Shen, Eijiro Nakamura, Kiyohiro Ando, Sabina Signoretti, Rameen Beroukhim, Glenn S Cowley, Patrick Lizotte, Ella Liberzon, Steven Bair and 12 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 164 citations in OpenAlex.

  1. Haematologica · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. The Roles of SQSTM1/p62 in Selective Autophagy and Oncogenic Signaling.International journal of molecular sciences · 2026
    Review
  6. Article
  7. Integrated analysis uncoversInternational journal of medical sciences · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Toward a CRISPR-based mouse model ofProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  20. Article

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Lianjie LiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Chuan ShenDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Eijiro NakamuraDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Kiyohiro AndoDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Sabina SignorettiDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Rameen BeroukhimDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Glenn S CowleyBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Patrick LizotteBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Ella LiberzonDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Steven BairDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
David E RootBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Pablo TamayoBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Aviad TsherniakBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Su-Chun ChengDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Barbara TabakDepartment of Cancer Biology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Anders JacobsenDepartment of Computational Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA.
A Ari HakimiDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA.
Nikolaus SchultzDepartment of Computational Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA.
Giovanni CirielloDepartment of Computational Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA.
Chris SanderDepartment of Computational Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA.
James J HsiehDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA; Department of Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA.
William G KaelinDepartment of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address: william_kaelin@dfci.harvard.edu.
Memorial Sloan Kettering Cancer Center · USBroad Institute · USBrigham and Women's Hospital · USHarvard University · USDana-Farber Cancer Institute · USDana-Farber Brigham Cancer Center · US

Funding

Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4M
UROLOGY ONCOLOGY RESEARCH TRAINING GRANTT32CA082088 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Brett Stewart Carver · 1999 to 2026
$7.1M
Knowledge-based Gene Expression Analysis for Biomedical and Cancer ResearchR01CA121941 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2006 to 2016
$5.1M
The von Hippel-Lindau Tumor Suppressor Protein:Roles in Cancer and Oxygen SensingR01CA068490 · NCI · DANA-FARBER CANCER INSTITUTE · PI KAELIN, WILLIAM G. · 1996 to 2015
$4.8M
Howard Hughes Medical InstituteNCI NIH HHS P50 CA101942NCI NIH HHS R01 CA068490NCI NIH HHS R01 CA121941NCI NIH HHS T32 CA082088
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and is often linked to loss of chromosome 3p, which harbors the VHL tumor suppressor gene, loss of chromosome 14q, which includes HIF1A, and gain of chromosome 5q. The relevant target(s) on chromosome 5q is not known. Here, we show that 5q amplification leads to overexpression of the SQSTM1 oncogene in ccRCC lines and tumors. Overexpression of SQSTM1 in ccRCC lines promoted resistance to redox stress and increased soft agar growth, while downregulation of SQSTM1 decreased resistance to redox stress, impaired cellular fitness, and decreased tumor formation. Therefore, the selection pressure to amplify 5q in ccRCC is driven, at least partly, by SQSTM1.

Indexed as

Chromosomes, Human, Pair 5Gene DosageAdaptor Proteins, Signal TransducingAnimalsBase SequenceCarcinoma, Renal CellCell Line, TumorHumansKidney NeoplasmsMiceMolecular Sequence DataNF-E2-Related Factor 2Sequestosome-1 ProteinAdaptor Proteins, Signal TransducingNFE2L2 protein, humanNF-E2-Related Factor 2Sequestosome-1 ProteinSQSTM1 protein, human

Identifiers

PMID24332042
PMCPMC3910168
OpenAlexW2059951699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.